Misa Naganuma, Kohei Tahara, Shiori Hasegawa, Akiho Fukuda, Sayaka Sasaoka, Haruna Hatahira, Yumi Motooka, Satoshi Nakao, Ririka Mukai, Kouseki Hirade, Tomoaki Yoshimura, Takeshi Kato, Hirofumi Takeuchi, Mitsuhiro Nakamura
OBJECTIVES: Paclitaxel is a highly effective antitumor agent with notable adverse events, including hypersensitivity reactions, peripheral neuropathy, arthralgia, myalgias, and neutropenia. Solvent-based paclitaxel causes severe allergic, hypersensitivity, and anaphylactic reactions. Nanoparticle albumin-bound paclitaxel was recently developed and provides an advantage over solvent-based paclitaxel in avoiding solvent/surfactant-related adverse events. The aim of this study was to assess the adverse event profiles of solvent-based paclitaxel and nanoparticle albumin-bound paclitaxel formulations using data from the spontaneous adverse event reporting system of the US Food and Drug Administration Adverse Event Reporting System database...
2019: SAGE Open Medicine